| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the latest quarter, 4 analysts provided ratings for Artivion (NYSE:AORT), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 0 | 0 | 0 |
| Last 30D | 2 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Artivion, revealing an average target of $40.5, a high estimate of $45.00, and a low estimate of $35.00. Marking an increase of 20.29%, the current average surpasses the previous average price target of $33.67.
The analysis of recent analyst actions sheds light on the perception of Artivion by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Daniel Stauder | JMP Securities | Raises | Market Outperform | $42.00 | $33.00 |
| Rick Wise | Stifel | Raises | Buy | $40.00 | $36.00 |
| Mike Matson | Needham | Raises | Buy | $45.00 | $32.00 |
| William Plovanic | Canaccord Genuity | Announces | Buy | $35.00 | - |
Capture valuable insights into Artivion's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Artivion analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Artivion showcased positive performance, achieving a revenue growth rate of 1.59% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Artivion's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -0.51%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Artivion's ROE excels beyond industry benchmarks, reaching -0.18%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Artivion's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.06%, the company showcases efficient use of assets and strong financial health.
Debt Management: Artivion's debt-to-equity ratio surpasses industry norms, standing at 1.23. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: AORT
